Penumbra Inc (PEN)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $12.65B
Last updated: Nov 17, 2026 at 11:05 AM ET
Penumbra Inc (PEN) Financials: Revenue, Profit and Cash Flow
Penumbra reported revenue of $1.40B for the fiscal year ended Dec 31, 2025, up 17.5% from the year before. That year, net income was $177.69M with a net margin of 12.7%, operating cash flow was $238.66M and free cash flow was $174.93M. The quarter ended Sep 30, 2026 had revenue of $410.14M and net income of $42.28M.
Revenue and Margins
The operating margin was 13.5% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $263.32M, a compound annual rate of 20.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.40B | +17.5% | 67.1% | 13.5% | 12.7% |
| Dec 2024 | $1.19B | +12.9% | 63.2% | 0.8% | 1.2% |
| Dec 2023 | $1.06B | +25.0% | 64.5% | 6.9% | 8.6% |
| Dec 2022 | $847.13M | +13.3% | 63.2% | 0.7% | -0.2% |
| Dec 2021 | $747.59M | +33.4% | 63.6% | -1.0% | 0.4% |
| Dec 2020 | $560.41M | +2.4% | 60.3% | -6.9% | -3.4% |
| Dec 2019 | $547.40M | +23.0% | 68.0% | 8.7% | 8.6% |
| Dec 2018 | $444.94M | +33.3% | 65.7% | -0.2% | 0.7% |
| Dec 2017 | $333.76M | +26.8% | 65.1% | 0.3% | 1.4% |
| Dec 2016 | $263.32M | N/A | 64.9% | -0.5% | 5.6% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 1168.3% from the year before. In the quarter ended Sep 2026, net income fell 7.8% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.40B | $1.19B | $1.06B | $847.13M | $747.59M | $560.41M | $547.40M | $444.94M | $333.76M | $263.32M |
| Cost of revenue | $461.23M | $439.62M | $375.88M | $311.93M | $272.21M | $222.24M | $175.44M | $152.41M | $116.62M | $92.49M |
| Gross profit | $942.44M | $755.00M | $682.64M | $535.21M | $475.38M | $338.18M | $371.96M | $292.53M | $217.14M | $170.83M |
| Research and development | $89.77M | $94.78M | $102.64M | $79.41M | $104.55M | $90.05M | $51.72M | $67.00M | $31.66M | $23.88M |
| Operating income | $189.25M | $9.28M | $73.55M | $6.08M | -$7.50M | -$38.94M | $47.51M | -$852.00K | $1.17M | -$1.35M |
| Net income | $177.69M | $14.01M | $90.95M | -$2.00M | $2.62M | -$19.26M | $47.00M | $2.91M | $4.66M | $14.81M |
| EBITDA | $222.60M | $44.57M | $106.91M | $28.21M | $5.91M | -$26.39M | $55.38M | $4.81M | $3.60M | $102.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $410.14M | $390.05M | $374.76M | $385.38M | $354.69M | $339.45M | $324.14M | $315.52M | $301.04M | $299.40M | $278.65M | $284.68M |
| Gross profit | $280.30M | $264.94M | $253.41M | $262.13M | $240.42M | $224.01M | $215.88M | $210.72M | $200.31M | $162.83M | $181.14M | $186.99M |
| Operating income | $50.74M | $41.04M | $38.23M | $59.23M | $48.84M | $40.83M | $40.35M | $42.77M | $35.36M | -$80.96M | $12.10M | $35.03M |
| Net income | $42.28M | $34.81M | $32.58M | $47.34M | $45.85M | $45.27M | $39.22M | $33.68M | $29.53M | -$60.20M | $11.00M | $54.22M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $16.23M by $170.66M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.83B | $1.53B | $1.56B | $1.37B | $1.24B | $822.98M | $665.90M | $557.86M | $476.67M | $308.25M |
| Current assets | $1.22B | $951.13M | $915.40M | $755.70M | $681.47M | $617.70M | $463.13M | $410.30M | $382.23M | $263.83M |
| Cash and equivalents | $186.90M | $324.40M | $167.49M | $69.86M | $59.38M | $69.67M | $72.78M | $67.85M | $50.64M | $13.24M |
| Total liabilities | $398.92M | $382.25M | $377.36M | $372.03M | $290.32M | $185.19M | $180.29M | $108.33M | $76.26M | $41.71M |
| Short-term debt | $16.23M | $14.59M | $13.43M | $11.95M | $9.98M | $6.03M | $8.31M | $0 | $0 | $0 |
| Shareholder equity | $1.43B | $1.15B | $1.18B | $998.86M | $953.93M | $641.50M | $485.89M | $0 | $400.41M | $266.55M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.03B | $1.97B | $1.90B | $1.83B | $1.74B | $1.67B | $1.59B | $1.53B | $1.48B | $1.53B | $1.58B | $1.56B |
| Total liabilities | $441.59M | $443.96M | $424.63M | $398.92M | $385.67M | $380.86M | $380.43M | $382.25M | $374.84M | $373.33M | $376.31M | $377.36M |
| Cash and equivalents | $254.28M | $205.27M | $241.29M | $186.90M | $321.03M | $421.77M | $376.05M | $324.40M | $280.48M | $288.33M | $223.11M | $167.49M |
| Shareholder equity | $1.58B | $1.53B | $1.47B | $1.43B | $1.36B | $1.29B | $1.21B | $1.15B | $1.10B | $1.16B | $1.20B | $1.18B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 73.3% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $238.66M | $168.48M | $97.33M | -$55.66M | $9.50M | -$33.24M | $26.65M | $28.81M | $12.69M | -$12.81M |
| Capital expenditures | $63.73M | $21.18M | $15.21M | $19.30M | $21.18M | $24.76M | $22.11M | $9.60M | $12.53M | $13.63M |
| Free cash flow | $174.93M | $147.30M | $82.12M | -$74.96M | -$11.68M | -$58.00M | $4.54M | $19.20M | $159.00K | -$26.44M |
| Dividends paid | N/A | N/A | N/A | $8.04M | $15.83M | $683.00K | $1.76M | $4.48M | $0 | $0 |
| Share repurchases | $0 | $100.39M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$404.59M | $77.62M | -$16.08M | $54.79M | -$21.73M | -$104.15M | -$12.71M | -$385.00K | -$77.65M | $687.00K |
| Financing cash flow | $26.53M | -$87.01M | $16.20M | $11.62M | $836.00K | $134.92M | -$8.96M | -$9.81M | $104.36M | $7.13M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $41.51M | $46.08M | $86.97M | $86.48M | $58.26M | $44.95M | $48.97M | $51.11M | $56.47M | $22.61M | $38.30M | $36.26M |
| Capital expenditures | $15.11M | $13.54M | $13.67M | $18.43M | $16.25M | $15.58M | $13.47M | $5.37M | $5.45M | $4.54M | $5.82M | $3.65M |
| Free cash flow | $26.40M | $32.54M | $73.30M | $68.05M | $42.01M | $29.37M | $35.50M | $45.74M | $51.02M | $18.07M | $32.47M | $32.62M |
Frequently Asked Questions About PEN
What is Penumbra's annual revenue?
Penumbra reported revenue of $1.40B for the fiscal year ended Dec 31, 2025.
How fast is Penumbra's revenue growing?
Revenue was up 17.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 18.3%.
Is Penumbra profitable?
Yes. Penumbra reported net income of $177.69M for the fiscal year ended Dec 31, 2025, with a net margin of 12.7%.
How much free cash flow does PEN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $238.66M minus capital expenditures of $63.73M produced free cash flow of $174.93M.
How much debt does Penumbra have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $16.23M and cash and equivalents of $186.90M.
PEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts